Dateline City:
WHITEHOUSE STATION, N.J. & WEST LAFAYETTE, Ind.
WHITEHOUSE STATION, N.J. & WEST LAFAYETTE, Ind.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and
Endocyte, Inc. (NASDAQ:ECYT), today announced that the Data Safety
Monitoring Board (DSMB) of the PROCEED trial has completed a
pre-specified, interim futility analysis and the DSMB recommended that
the trial be stopped because vintafolide did not demonstrate efficacy on
the pre-specified outcome of Progression-Free Survival (PFS) in patients
with platinum-resistant ovarian cancer.
Language:
English
Contact:
MerckMedia:Ian McConnell, +1 908-423-3046Claire Mulhearn, +1 908-423-7425orInvestors:Carol Ferguson, +1 908-423-4465Justin Holko, +1 908-423-5088orEndocyteMedia:Martina Schwarzkopf, +1 212-845-4292Tony Russo, +1 212-845-4251orInvestors:Stephanie Ascher, +1 212-362-1200
Ticker Slug:
Ticker: MRK Exchange: NYSE
Ticker: ECYT Exchange: NASDAQ
read more